The State of Outsourcing Partnerships - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The State of Outsourcing Partnerships
Preferred-provider relationships are transforming the bio/pharmaceutical industry.


Pharmaceutical Technology


Implications for the business model

One of the most interesting aspects of the growth of these strategic sourcing arrangements is the impact on business-development activities at the large CROs. Senior executives at the major CROs believe that no more than half of the potential deals for clinical services have been done, and less than that for preclinical services. The greatest fear among these companies is that if they lose out on a strategic opportunity with a bio/pharma company, it will be a long time before they get to do business with that company again. As a result, the CROs are being aggressive in going after these deals. They are bidding them at fairly low prices to lock in relationships with the hope that lower sales expenses, greater visibility to workflows, and opportunities for add-on work will boost their margins over the longer term.


Table I: Major preferred-provider relationships in clinical research.
The big CROs also believe that the ability to offer a broad range of integrated services is important to winning strategic deals. The initial preferred-provider contracts often involved primarily data-management and site-management activities, but companies realize that being able to offer a broader range of services can make them more competitive. This increase in services has driven acquisition and alliance activity to add crucial services, such as bioanalytical testing, and to broaden geographic coverage.

Going beyond clinical research

Preferred-provider deals have primarily been struck (or at least announced) in the clinical-research arena (see Table I), but they are beginning to spread into other R&D activities. In a recent presentation at the JP Morgan Healthcare Conference in San Francisco in January 2013, the CEO of Charles River Laboratories, James Foster, said that strategic sourcing activity had "reached an inflection point" in the preclinical research area. Charles River had secured several such deals recently and has seen more such deals in the pipeline. Activities supporting drug discovery, which by most accounts have been only minimally outsourced to this point, is another area on the verge of considerable growth.

In the areas of developing and manufacturing APIs and drug products, few preferred-provider relationships have been established thus far. Outsourcing trends in these areas have traditionally lagged those in clinical research by as much as five years, and are complicated by the vast array of process and delivery technologies that are required to support a typical global bio/pharma company's portfolio. There have been a few noteworthy successes, especially in clinical packaging, where as many as half of global bio/pharmaceutical companies have established preferred relationships with one of the three major clinical packagers. Bio/pharma companies are also showing increased interest in models that hand-off all aspects of product development, from clinical through commercial, to a single CDMO.

This is a time of great experimentation with new business models at global bio/pharma companies, and we are likely to see many variations on the preferred-provider model in coming years. This new environment will call for a combination of vision and operating skill on the part of CRO and CMO executives as they help define the bio/pharma business model of the future.

Jim Miller is president of PharmSource Information Services and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903,
, http://www.pharmsource.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here